Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration

Published:2020-06-01 Issue:7 Volume:29 Page:651-658
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Ferro Desideri Lorenzo¹,Traverso Carlo Enrico¹²,Nicolò Massimo¹²³

Affiliation:

1. IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genoa, Italy

2. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (Dinogmi), University of Genoa, Genoa, Italy

3. Macula Onlus Foundation, Genoa, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1772754

Reference42 articles.

1. Age-related macular degeneration

2. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

3. Age-Related Macular Degeneration

4. Mechanisms of Age-Related Macular Degeneration

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical, functional and aberrometric parallels in the treatment of the neovascular form of age-related macular degeneration;Russian Ophthalmological Journal;2024-06-27

2. Applications of nanomaterials in anti‐VEGF treatment for ophthalmic diseases;Journal of Biomedical Materials Research Part A;2023-10-18

3. An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye;ACS Omega;2023-09-22

4. Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy;Frontiers in Bioengineering and Biotechnology;2023-05-23

5. Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration;Pharmaceutics;2023-05-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3